- Home
- ARRY vs ANAB Comparison
ARRY vs ANAB Comparison
Compare ARRY & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARRY
- ANAB
- Stock Information
- Founded
- ARRY 1989
- ANAB 2005
- Country
- ARRY United States
- ANAB United States
- Employees
- ARRY N/A
- ANAB N/A
- Industry
- ARRY Semiconductors
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ARRY Technology
- ANAB Health Care
- Exchange
- ARRY Nasdaq
- ANAB Nasdaq
- Market Cap
- ARRY 1.1B
- ANAB 1.0B
- IPO Year
- ARRY 2020
- ANAB 2017
- Fundamental
- Price
- ARRY $7.53
- ANAB $42.39
- Analyst Decision
- ARRY Buy
- ANAB Buy
- Analyst Count
- ARRY 20
- ANAB 12
- Target Price
- ARRY $10.38
- ANAB $63.80
- AVG Volume (30 Days)
- ARRY 7.9M
- ANAB 718.0K
- Earning Date
- ARRY 11-05-2025
- ANAB 11-04-2025
- Dividend Yield
- ARRY N/A
- ANAB N/A
- EPS Growth
- ARRY N/A
- ANAB N/A
- EPS
- ARRY N/A
- ANAB N/A
- Revenue
- ARRY $1,333,329,000.00
- ANAB $169,467,000.00
- Revenue This Year
- ARRY $34.42
- ANAB $37.52
- Revenue Next Year
- ARRY $14.70
- ANAB N/A
- P/E Ratio
- ARRY N/A
- ANAB N/A
- Revenue Growth
- ARRY 35.75
- ANAB 196.42
- 52 Week Low
- ARRY $3.76
- ANAB $12.21
- 52 Week High
- ARRY $10.37
- ANAB $43.31
- Technical
- Relative Strength Index (RSI)
- ARRY 45.50
- ANAB 71.33
- Support Level
- ARRY $6.93
- ANAB $33.10
- Resistance Level
- ARRY $7.62
- ANAB $43.31
- Average True Range (ATR)
- ARRY 0.66
- ANAB 2.88
- MACD
- ARRY -0.07
- ANAB 0.51
- Stochastic Oscillator
- ARRY 33.12
- ANAB 91.49
About ARRY Array Technologies Inc.
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers referred to as a single-axis tracker that move solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil and Rest of the World with the United States deriving the majority of the revenue.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).